U.S., Feb. 19 -- ClinicalTrials.gov registry received information related to the study (NCT03836638) titled 'The Impact of Age on Botulinum Toxin Potency in Facial Rhytides Treatment' on Aug. 24, 2018.
Brief Summary: Botulinum toxin is approved by the FDA for the treatment of facial wrinkles. Patients are usually older than 45 years and their main demand is to treat pre-existing facial wrinkles. However with the increasing popularity of this technique, younger patients, aged 25 to 35 years, are now seeking botulinum toxin injection as a preventive measure for rhytides. The usual dose used for the treatment of facial rhytides in a female patient older than 45 years is 50 units. No consensus exists concerning the dose of botulinum toxin that...